Cancers de la sphère ORL : l’immunothérapie donne de la voix ! [Head and neck cancer : promising results of immunotherapy]
Details
Serval ID
serval:BIB_FFCBF161F44F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Cancers de la sphère ORL : l’immunothérapie donne de la voix ! [Head and neck cancer : promising results of immunotherapy]
Journal
Revue medicale suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
17/05/2017
Peer-reviewed
Oui
Volume
13
Number
563
Pages
1029-1031
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
Immunotherapy, especially checkpoint inhibitors such as anti-PD1 and anti-PDL1 antibodies, has changed the standard of care and the prognosis of melanoma, but also more recently of lung cancer, renal cancer and Hodgkin lymphoma. Results of preliminary studies in head and neck squamous cell carcinoma (HNSCC) as well as in less frequent tumors of the region, such as nasopharyngeal carcinoma and high grade salivary gland carcinoma, are also promising. Indeed, in a recent phase 3 study, the PD1 inhibitor nivolumab has recently demonstrated a significant improvement in overall survival for platin-resistant recurrent and/or metastatic HNSCC.
Keywords
Carcinoma/pathology, Carcinoma/therapy, Carcinoma, Squamous Cell/pathology, Carcinoma, Squamous Cell/therapy, Head and Neck Neoplasms/pathology, Head and Neck Neoplasms/therapy, Humans, Immunotherapy/methods, Immunotherapy/trends, Melanoma/pathology, Melanoma/therapy, Nasopharyngeal Neoplasms/pathology, Nasopharyngeal Neoplasms/therapy
Pubmed
Create date
22/06/2017 21:21
Last modification date
03/04/2023 11:43